# AstraZeneca at a Glance

We are a global, science-led, patient-focused pharmaceutical company. We are dedicated to transforming the future of healthcare by unlocking the power of what science can do for people, society and the planet.

## Our strategic priorities

Our priorities reflect how we are working to deliver our Growth Through Innovation strategy and achieve our Purpose of pushing the boundaries of science to deliver life-changing medicines.

1. Science and Innovation
2. Growth and Therapy Area Leadership
3. People and Sustainability

## Science and innovation-led

We invest in new technologies and modalities to deliver the next wave of pipeline innovation and life-changing medicines.

**191** projects in our development pipeline[1]

**19** new molecular entities (NMEs) in our late-stage pipeline

**130** NME or major life-cycle management (LCM) projects in Phase II and Phase III

**$13.6bn** invested in our science

[1] Includes NME and major LCM projects up to launch in all applicable major markets.

## Leading in our therapy areas

We focus on areas where we can transform patient outcomes through novel medicines and combinations.

### Total Revenue by therapy area[2]



- $22.4bn, 41% Oncology
- $21.9bn, 40% BioPharmaceuticals
- $8.8bn, 16% Rare Disease
- $1.1bn, 2% Other Medicines

### Total Revenue

**$54.1bn**




[2] Due to rounding, the sum of subtotals and percentages may not agree to totals.

## Diversified portfolio and global reach

We deliver a diversified portfolio of medicines across primary care, specialty care and rare diseases through our broad-based network and increasing presence in emerging markets.

### Total Revenue by reporting region



- $23.2bn, 43%
- $13.7bn, 25%
- $12.2bn, 23%
- $5.0bn, 9%

### Total Revenue growth by reporting region[3]




[3] Actual growth percentage.

**Key**

US · Emerging Markets · Europe · Established Rest of World

## Positively impacting the health of people, society and the planet BV

We operate responsibly, harnessing the power of science and innovation, and our global reach, to help build a healthier, more sustainable future.

**90.5m** people reached by our access to healthcare programmes

**77.5%** reduction in Scope 1 and 2 GHG emissions since 2015

MSCI ESG RATINGS AA

Rating of AA in the MSCI ESG Ratings assessment

access to medicine FOUNDATION

Ranked in the top five of the Access to Medicine Index 2024